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AbstrAct
Background The European Society for Medical Oncology- 
Magnitude of Clinical Benefit Scale (ESMO- MCBS) is 
a validated value scale for solid tumour anticancer 
treatments. Form 1 of the ESMO- MCBS, used to grade 
therapies with curative intent including adjuvant therapies, 
has only been evaluated for a limited number of studies. 
This is the first large- scale field testing in early breast 
cancer to assess the applicability of the scale to this 
data set and the reasonableness of derived scores and 
to identify any shortcomings to be addressed in future 
modifications of the scale.
Method Representative key studies and meta- analyses 
of the major modalities of adjuvant systemic therapy of 
breast cancer were identified for each of the major clinical 
scenarios (HER2- positive, HER2- negative, endocrine- 
responsive) and were graded with form 1 of the ESMO- 
MCBS. These generated scores were reviewed by a panel 
of experts for reasonableness. Shortcomings and issues 
related to the application of the scale and interpretation of 
results were identified and critically evaluated.
Results Sixty- five studies were eligible for evaluation: 
59 individual studies and 6 meta- analyses. These studies 
incorporated 101 therapeutic comparisons, 61 of which 
were scorable. Review of the generated scores indicated 
that, with few exceptions, they generally reflected 
contemporary standards of practice. Six shortcomings 
were identified related to grading based on disease- free 
survival (DFS), lack of information regarding acute and 
long- term toxicity and an inability to grade single- arm 
de- escalation scales.
Conclusions Form 1 of the ESMO- MCBS is a robust tool 
for the evaluation of the magnitude of benefit studies in 
early breast cancer. The scale can be further improved 
by addressing issues related to grading based on DFS, 
annotating grades with information regarding acute and 
long- term toxicity and developing an approach to grade 
single- arm de- escalation studies.
IntRoduCtIon
As the population ages, the incidence 
and prevalence of cancer are expected to 
continue to rise both in developed1 and devel-
oping countries.2 The estimated total annual 
economic cost of cancer was US$1.16 trillion 
in 2010, about 2% of global gross domestic 
product3 and is continuing to rise exponen-
tially. Breast cancer remains the leading cause 
of cancer among women2 and the ongoing 
care of breast cancer patients is estimated to 
be one of the most significant contributors to 
growing cancer care expenditure.4
These considerations underscore the 
need for validated tools to evaluate value of 
care, where value is recognised as a balance 
between clinical benefit and cost. With this in 
mind, both the European Society for Medical 
Oncology (ESMO) and the American Society 
of Clinical Oncology (ASCO) established 
Click here to listen to the Podcast
Key questions
What is already known about this subject?
 ► Form 1 of the European Society for Medical 
Oncology- Magnitude of Clinical Benefit Scale 
(ESMO- MCBS) serves to score therapies with cu-
rative intent. To date, very limited field testing has 
been performed to assess the scale in the curative 
setting.
What does this study add?
 ► We evaluated the applicability of the scale and as-
sessed the reasonableness of the generated scores 
in early breast cancer. Form 1 of the ESMO- MCBS 
V.1.1 provided a generally robust tool for scoring of 
adjuvant breast cancer studies. Six shortcomings 
were identified including lack of information regard-
ing acute and long- term toxicity, an inability to grade 
single- arm de- escalation scales and limitations re-
lated to grading based on disease- free survival.
How might this impact on clinical practice?
 ► The identified shortcomings in form 1 of the ESMO- 
MCBS V.1.1 will be rectified in the upcoming version 
2.0 of the scale to strengthen the validity of that 
scale and its generated results. These developments 
have important implications for data interpretation, 
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Working Groups to address these issues and they have 
developed and published a platform for evaluating new 
anticancer therapeutics—the ESMO- Magnitude of Clin-
ical Benefit Scale (ESMO- MCBS)5 and the ASCO Frame-
work for assessing value of cancer care.6
The ESMO- MCBS was initially launched and published 
in 20155 and revised in 2017 with version 1.1.7 The scale 
aims to provide a validated and rational stratification 
process for oncology therapies, and its development 
process has been predicated on ‘accountability for reason-
ableness’ which incorporated extensive field testing and 
the peer review of results for ‘reasonableness’.7 Form 1 of 
the ESMO- MCBS, which is used to grade therapies with 
curative intent including adjuvant therapies, hitherto, has 
only been applied in a limited number of studies. Form 1 
of the ESMO- MCBS grades therapies with curative intent 
on a three- point scale A, B and C where scores of A and B 
represent substantial improvement.
This is the first large- scale field testing of form 1 in early 
breast cancer to assess the applicability of the ESMO- 
MCBS in this setting, to determine whether the scoring 
reflected clinical practice (reasonableness) and to iden-
tify shortcomings to be addressed in future versions of the 
scale. It also provides an overview of the magnitude of 
benefit for the most common therapies/therapeutic strat-
egies in the field of breast cancer, allowing for a critical 
reassessment of available options.
MetHodology
ESMO- MCBS V.1.1 form 1, designed to evaluate adjuvant 
and neoadjuvant studies, was applied to all the selected 
studies (online supplementary data).
Representative key studies and meta- analyses of the 
major modalities of adjuvant systemic therapy of breast 
cancer (chemotherapy or endocrine therapy or anti- HER2 
therapy) were identified for each of the major clinical 
scenarios (HER2- positive, HER2- negative, endocrine- 
responsive). Studies were identified through PubMed, 
Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) registration sites. Pivotal phase 
3 studies that have formed the basis for contemporary 
treatment practice and a randomised phase 2 study that 
resulted in preliminary drug registration8 were scored.
To identify the pivotal phase 3 studies, a PubMed search 
was performed with the following search criteria: “breast 
cancer”[Title] AND breast[Title] AND cancer[Title] AND 
adjuvant[Title] OR neo- adjuvant AND “2002”[Date—Pub-
lication] : “2019”[Date—Publication] AND English[Lan-
guage] AND “randomized controlled trial” OR “phase 
3” OR “randomized phase 2” NOT retrospective[Title/
Abstract] NOT historical[Title/Abstract] NOT “system-
atic review”[Title] NOT advanced[Title] NOT metastat-
ic[Title] NOT irradiation[Title] NOT safety[Title] NOT 
insights[Title] NOT observations[Title] NOT “quality of 
life”[Title] NOT biosimilar[Title] NOT analysis[Title] 
NOT analyses[Title] NOT radiation[Title]. There were 
597 studies identified from the search. Relevant studies 
that were comparative phase 3 randomised controlled 
studies were identified and subsequently cross- referenced 
with the FDA and EMA registration sites and ESMO9 and 
National Comprehensive Cancer Network (NCCN)10 
guidelines to identify pivotal and practice changing 
studies. Key meta- analyses referenced by ESMO9 and 
NCCN10 guidelines were identified.
Studies were eligible for scoring if they were randomised 
comparative studies comparing new therapies to stan-
dard of care or meta- analyses of those studies. Studies 
were scored if they met the scoring criteria defined by 
the ESMO- MCBS guideline according to the criteria in 
form 1. Where missing data impeded scoring, the corre-
sponding author was contacted with a request for data or 
clarification. If no response was received, the study was 
either marked as not scorable (this occurred for only one 
study11 and one meta- analysis12) or excluded (if there was 
inadequate data reported). All scoring was reviewed for 
accuracy by members of the Magnitude of Clinical Benefit 
Working Group and the generated scores were reviewed 
by the ESMO Breast Cancer Faculty for reasonableness.
Scoring was performed in accordance with the rules for 
application of the ESMO- MCBS.5 7 Studies initially evalu-
ated based on disease- free survival (DFS) criteria alone 
or pathological complete remission (pCR) rate were 
re- evaluated when mature overall survival (OS) data are 
available and a final score was determined based on these 
OS results. The only exception was for studies that were 
un- blinded after compelling early DFS results with subse-
quent access to the superior arm, whereby OS results 
were contaminated by the crossover and therefore were 
not evaluable.
Studies that could not be scored were classified into one 
of three groups: (1) studies that did not achieve statistical 
significance, designated ‘no evaluable benefit’ (NEB), (2) 
non- inferiority studies in which non- inferiority was not 
verified, designated ‘negative non- inferiority’ (NNI), (3) 
studies that could not be scored because required data 
were not included in the publication, designated ‘scoring 
not applicable’ (SNA) and (4) not- scorable subgroup 
data
Results
Sixty- five studies were eligible for evaluation: 59 individual 
studies and 6 meta- analyses (5 of which were individual 
patient- level data meta- analyses), which yielded data rele-
vant to 101 therapeutic comparisons, 61 of which demon-
strated significant benefit or non- inferiority and could be 
scored.
Adjuvant chemotherapy
Polychemotherapy versus no chemotherapy
Both cyclophosphamide methotrexate and 5- fluorouracil 
(CMF) and anthracycline- based therapy were found to be 
superior to no chemotherapy (in a predominantly node- 
positive population), both scoring an A compared with 
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in breast cancer mortality of 6.2% and 6.5%, respective-
ly(table 1).13
CMF versus anthracyclines
Four cycles of doxorubicin and cyclophosphamide 
(AC×4) were not found to be superior to CMF×6 in the 
meta- analysis.13 Benefit of CAF (cyclophosphamide/
doxorubicin/fluorouracil)/FEC×6 (fluorouracil/epiru-
bicin/cyclophosphamide) over CMF×6 was not reported 
in individual studies,14 15 but was demonstrated in a meta- 
analysis, with a 10- year OS gain of approximately 4% 
(grade B) (table 1).13
Taxanes
The three studies that evaluated the addition of a taxane 
to an anthracycline- based regimen all demonstrated gains 
in DFS, but mature survival data was available for only 
one of these studies with no significant survival advan-
tage and therefore classified as NEB.16–18 The MA-21 
study compared AC×4 followed by paclitaxel to both 
cyclophosphamide/epirubicin/fluorouracil (CEF) and 
dose- dense (dd) epirubicin/cyclophosphamide followed 
by paclitaxel in patients with node- positive and high- risk 
node- negative disease.19 Both study regimens demon-
strated superiority to AC×4 followed by paclitaxel based 
on 30- month DFS gain with no OS data available (grade 
A) (table 2).
In a meta- analysis, the addition of a taxane to an anthra-
cycline demonstrated a small survival advantage at 8 years 
follow- up (grade C).13 In this meta- analysis, the assessed 
cohorts consisted predominantly of patients with node- 
positive disease.
Docetaxel and cyclophosphamide (TC) ×4 was superior 
to AC×4, demonstrating a 6% gain in OS at 7- year median 
follow- up (grade A).20 21 However, a joint analysis of three 
trials comparing TC×6 to combinations including AC 
and a taxane did not establish non- inferiority of TC×6 
when compared with a combined taxane–anthracycline 
regimens.22
Other chemotherapy regimens
In all the dose- dense(dd) regimen trials, the high- risk, 
node- positive population demonstrated OS advantage 
(two studies in grade B, one study in grade C).23–25 The 
two studies with longest median follow- up achieved the 
highest grades.24 25 Two meta- analyses confirmed the 
superiority of dd regimens over standard scheduling 
(table 3).26 27
Post- neoadjuvant capecitabine for patients with incom-
plete pathological response after neoadjuvant therapy 
demonstrated survival benefit of more than 5%, at a 
median of 3.6- year follow- up for the intention- to- treat 
(ITT) population and for the triple negative subgroup 
(grade A).28
The addition of neoadjuvant carboplatin for patients 
with triple negative breast cancer demonstrated a benefit 
in the GeparSixto study for both pCR and DFS with an 
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BRIGHTNESS study of 15.8% compared with the non- 
carboplatin arm.30 The CALGB 40603 did not demonstrate 
an outcome benefit from the addition of neoadjuvant 
carboplatin or bevacizumab despite improvements in 
pCR and was categorised as NEB.31
In the NSABP B40 study, there was no benefit of the addi-
tion of gemcitabine or capecitabine to standard neoad-
juvant chemotherapy regimens.11 32 This study reported 
an OS benefit from the addition of neoadjuvant bevaci-
zumab with a HR of 0.65 (95% CI 0.49–0.88); however, 
since the absolute survival benefit was not published, this 
was not evaluable (SNA).11
In the GeparSepto study, neoadjuvant nab- paclitaxel 
demonstrated a limited improvement in pCR rate 
compared with paclitaxel, however the gain was below the 
ESMO- MCBS threshold for scoring the ≥30% relative and 
>15% absolute pCR gain).33
Anti-HeR2 therapies
Trastuzumab
All the 12- month adjuvant trastuzumab studies demon-
strated substantial benefit (grade A or B).34–36 Two years 
of trastuzumab was not superior to 12 months.34 While 
several studies failed to demonstrate non- inferiority of 
shorter duration of trastuzumab therapy,37–39 the PERSE-
PHONE study demonstrated non- inferiority for 6 months 
versus 12 months of trastuzumab and scored a B based on 
non- inferiority and reduced cost (table 4).40
Dual blockade
Four of the five studies testing double blockade with tras-
tuzumab plus a second anti- HER2 agent derived scores 
based on surrogate outcomes of pCR for neoadjuvant 
studies or DFS (table 5).
In the APHINITY study, evaluating the addition of 
pertuzumab to trastuzumab, the ITT population scored 
grade B.41 The node- positive subgroup was not scorable 
since this was 1 of 12 evaluated subgroups in an explor-
atory analysis and was, therefore, not eligible for grading 
(of note, the ESMO- MCBS allows only for scoring 
of subgroups only if there were up to three planned 
subgroups in the study design).41
Based on pCR criteria, the NeoSphere study (without 
published OS data) was graded C8 in contrast to the Neo- 
ALTTO study, which had a similar pCR gain but no OS 
benefit.42 43
Second-generation anti-HER2 therapies
In the ExteNET study, the addition of neratinib for 
node- positive or locally advanced breast cancer after 
completion of adjuvant trastuzumab scored a grade A 
(table 5).44
In patients with residual disease after neoadjuvant anti- 
HER2- based therapy, completing 1 year of trastuzumab 
emtansine (T- DM1) demonstrated large improvement in 
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The addition of 5 years of tamoxifen compared with 
placebo was graded an A based on increased long- term 
OS by 6% and 9% at the individual trial level and in the 
meta- analysis level, respectively (table 6).46 47
Aromatase Inhibitors
The aromatase inhibitor studies to score an A were 
the Intergroup Exemestane(IES) study and the Italian 
Tamoxifen Anastrozole (ITA) study. The ITA study score 
was credited based on DFS results alone in the absence 
of mature OS data.48 Among the five studies with mature 
OS data, the data in two did not meet significance thresh-
olds49–52 and the OS gain merited scores of B53–55 or C 
in the other three.56–58 Comparison aromatase inhib-
itor alone for 5 years with a switch regimen including 
tamoxifen and an aromatase inhibitor (2.5 years each) 
were credited on the basis of non- inferiority in OS and 
reduced toxicity compared with aromatase inhibitor 
alone (table 7).52 55 59 60
Meta- analysis data resulted in a C score for the use of an 
aromatase inhibitor alone in the adjuvant setting, and a C 
when used a part of a switch after tamoxifen.60
In the premenopausal population, the addition of an 
aromatase inhibitor (with ovarian function suppression) 
scored a C when compared with tamoxifen with ovarian 
function suppression, in the combined SOFT- TEXT 
study,61–63 but it did not score in the ABCSG-12 study.64
Extended endocrine therapy
In the MA-17 study of 5 years letrozole or placebo after 
5 years tamoxifen, the node- positive subgroup scored 
A based on DFS criteria.65 66 Other studies of extended 
aromatase inhibitor failed to demonstrate improvement 
in OS.67–69 The ATLAS (Adjuvant Tamoxifen: Longer 
Against Shorter) study of 5 years versus 10 years of adju-
vant tamoxifen demonstrated a 2.8% reduction in breast 
cancer mortality (grade C) (table 8).70
Ovarian function suppression in premenopausal women
Three studies were evaluated. Two mature studies did 
not demonstrate significant OS gain.61 64 71 72 In the SOFT 
study, a 1.8% OS advantage was observed in the tamoxifen 
with ovarian function suppression (OFS) arm, scoring a 
C, and in the subgroup of patients who had received prior 
chemotherapy the observed gain in OS was 4.3% (grade 
B) (table 9).63
Adjuvant bone-modifying agents
None of the six individual studies demonstrated a survival 
advantage. A meta- analysis identified a reduction in breast 
cancer mortality of 1.8% (grade C), largely derived from 
the benefit observed in postmenopausal subgroup where 
the benefit was 3.3% (grade B) (table 10).73
expert peer review of the generated results
The scores generated in this field testing were reviewed 
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Apart from the scores for double HER2 blockade, the 
derived scores were more commonly endorsed as reason-
able than unreasonable. There was no consensus about 
the grading for double HER2 blockade (unreasonable 
32%; reasonable 29%): many respondents expounded 
that the scores for the APHINITY and ExteNET studies, 
derived from the relative benefit gain in DFS but with 
very small absolute benefit, were excessively high. In situ-
ations when the primary outcome of the study was DFS, 
and a robust DFS benefit was observed (in terms of both 
relative and absolute benefits) but without significant OS 
benefit, a proportion of reviewers expressed that a grade 
of NEB under represented the clinical value of prolonged 
interim time without disease, treatment and toxicity.
dIsCussIon
The validity of the ESMO- MCBS is predicated on adher-
ence to the public policy ethical standard of ‘accounta-
bility for reasonableness’ and the field testing of the scale 
over a large range of clinical trials is an important part of 
the development process. This study, applying the ESMO- 
MCBS V.1.1 to 59 individual trials and 6 meta- analyses, 
has demonstrated that form 1 of the ESMO- MCBS can 
be applied to systemic adjuvant therapy trials. More-
over, apart from a few specific exceptions, the generated 
grades were considered reasonable by experts in the 
ESMO Breast Cancer Faculty, largely reflecting standard 
clinical practice.
Applying the scale and interpreting the results was, 
in most instances, straightforward. A small number of 
studies did not incorporate all critical data in accor-
dance with CONSORT standards. In some instances HRs 
were published without CIs, some meta- analyses did not 
include absolute gain data for OS12 and some studies 
report the HR to reflect increased recurrence risk (eg, 
MA-21).19 Furthermore, even with long- term follow- up, 
some studies never published follow- up of their mature 
survival data. Since magnitude of benefit grades derived 
from OS gain at maturity is often less than that derived 
from DFS, the non- publication of mature OS results occa-
sionally resulted in disproportionally high scores in some 
studies. This is well illustrated in two examples: no mature 
survival data were ever published for the ITA study by 
Boccardo et al which evaluated switching from tamox-
ifen to an aromatase inhibitor48 and the MA21 study that 
evaluated the addition of paclitaxel to an anthracycline.19 
Consequently, these were among the few studies in their 
respective classes to score an A, while all others for which 
mature survival data were available scored C or NEB. We 
note that this anomaly could be misinterpreted to suggest 
superiority, or even manipulated with delays or even non- 
reporting of mature OS data to avoid downgrading.
We note that the ESMO- MCBS is agnostic to DFS type 
and does not distinguish between DFS, invasive DFS 
(iDFS) and distant DFS (DDFS) that is also called ‘distant 
metastasis- free survival’. In recent years, there has been 
a shift to more accurate end points such as invasive iDFS 
or DDFS, which are better surrogates for OS benefit,74 
since they emphasise events that are more closely related 
to cancer mortality (ie, invasive relapse or distant metas-
tases). This underscores the importance of new initiatives 
to introduce standardisation in the definitions and appli-
cation of these end points.74 75
A key aim of this study was to identify shortcomings in 
the current version of form 1 which will be addressed in 
future versions of the scale. This field testing and peer- 
review process identified six shortcomings in form 1. All 
of these shortcomings have been reviewed by the ESMO- 
MCBS Working Group and initiatives are underway to 
address each of them as part of the forthcoming revisions 
to be incorporated in the next version of the scale (V.2.0).
1. HR thresholds for DFS are excessively lenient: The expe-
rience of this field testing indicates that trials initially 
graded on the basis of DFS in initial publications, 
commonly attained lower scores when mature OS data 
were available and that in many cases the OS gains were 
not significant. This indicates that the relative benefit 
thresholds for grade B and C (lower limit of the 95% CI 
of the HR 0.65–0.85 and >0.85, respectively) are exces-
sively lenient. Consequently, we recommend lowering of 
the HR thresholds for grades B and C.
2. Lack of absolute gain constraint on DFS scoring can 
generate inappropriately high scores when absolute gain is 
very small: Expert peer reviewers concerned that grades 
accrued on the basis of relative benefit when the observed 
absolute benefit is very small were unreasonably high. 
This was highlighted in their critique of scores gener-
ated in the APHINITY41 and ExteNET44 trials. This could 
be corrected by applying the ‘dual rule’ whereby grade 
criteria include both relative and absolute benefit thresh-
olds in a manner that is constant with all other forms of 
the ESMO- MCBS V.1.1.
3. The clinical benefit derived from DFS gain is not credited 
when OS gain is not verified. In many instances, gains derived 
from DFS were not credited when there was no significant gain 
in mature OS. When substantially improved DFS does not 
result in improved OS, the grading of NEB undervalued 
the time gained without need for medical treatment, 
which may itself be a valued outcome independent of 
OS.76
4. Need to define OS maturity in adjuvant studies: According 
to the ESMO- MCBS V.1.1, surrogate scores prevail if 
mature OS data are not yet available. Maturity is generally 
defined as the time point where most of the anticipated 
events will have occurred. In a non- curative setting, when 
all patients are expected to die, conventionally it is when 
the median survival of both arms is reached. However, 
in the adjuvant setting, when the number of anticipated 
events may vary according to the tumour type and stage, 
this convention does not apply.
Consequently, evaluating maturity of survival data in 
this setting requires familiarity with the specific clinical 
scenario and it is conceivable that in some instances 
this may be source of reasonable disagreement even 
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should include guidelines for OS maturity. For example, 
5 years for subtypes at high risk for earlier recurrence 
(such as triple negative and HER2- positive/endocrine 
unresponsive subtypes) and at least 8 years for endo-
crine responsive tumours (including HER2- positive/
endocrine- responsive).77
5. Lack of capacity to grade single- arm de- escalation studies 
in the curative setting: A recent single- arm phase 2 study 
reported excellent outcomes for node- negative HER2- 
positive breast cancers smaller than 2 cm treated with 
the combination of paclitaxel and trastuzumab (without 
an anthracycline).78 These type of studies are often used 
to evaluate de- escalation strategies. Form 1 is unable to 
grade these studies.
6. Lack of consideration of toxicity in the curative setting: 
The current version of form 1 does not consider toxicity. 
The shortcoming of this approach is illustrated by the 
ExteNET study that scores an ‘A’ for the hormone- positive 
subgroup despite very substantial toxicity secondary to 
the neratinib, which resulted in a 27.6% discontinuation 
rate.44 While we appreciate that patients may be willing to 
make short- term toxicity trade- off to improve cure rate, 
it is not clear that this approach applies also for long- 
term toxicity such as peripheral neuropathy or secondary 
cancers (especially when improvement in cure rate may 
be small). We support the proposition, initially made 
by patient advocacy groups, that ESMO- MCBS scores in 
form 1 should be annotated to indicate acute and/or 
long- term toxicities.
ConClusIons
In a time of exponential growth in the costs of cancer 
care, tools to assist physicians and regulatory bodies in 
evaluating new therapeutic options are critical. This study 
reinforces the validity of the ESMO- MCBS approach 
to adjuvant therapies insofar as the scoring of adjuvant 
approaches in early breast cancer largely reflects standard 
clinical practice. This field testing has identified six short-
comings that have been reviewed by the ESMO- MCBS 
Working Group and that form the foundation for amend-
ments to be incorporated into future iterations of the 
ESMO- MCBS.
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